PL3415616T3 - Sposób odmładzania komórek - Google Patents

Sposób odmładzania komórek

Info

Publication number
PL3415616T3
PL3415616T3 PL18183987.9T PL18183987T PL3415616T3 PL 3415616 T3 PL3415616 T3 PL 3415616T3 PL 18183987 T PL18183987 T PL 18183987T PL 3415616 T3 PL3415616 T3 PL 3415616T3
Authority
PL
Poland
Prior art keywords
rejuvenation method
cell rejuvenation
cell
rejuvenation
Prior art date
Application number
PL18183987.9T
Other languages
English (en)
Inventor
Alexandre PRIEUR
Ollivier MILHAVET
Jean-Marc Lemaitre
Laure LAPASSET
Original Assignee
INSERM (Institut National de la Santé et de la Recherche Médicale)
Centre National De La Recherche Scientifique - Cnrs
Université De Montpellier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by INSERM (Institut National de la Santé et de la Recherche Médicale), Centre National De La Recherche Scientifique - Cnrs, Université De Montpellier filed Critical INSERM (Institut National de la Santé et de la Recherche Médicale)
Publication of PL3415616T3 publication Critical patent/PL3415616T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/602—Sox-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/603—Oct-3/4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/604—Klf-4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/605—Nanog
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/606—Transcription factors c-Myc
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/608—Lin28
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
    • C12N2506/1307—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from adult fibroblasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Transplantation (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL18183987.9T 2011-04-08 2012-04-10 Sposób odmładzania komórek PL3415616T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11161771 2011-04-08

Publications (1)

Publication Number Publication Date
PL3415616T3 true PL3415616T3 (pl) 2024-10-14

Family

ID=45094314

Family Applications (2)

Application Number Title Priority Date Filing Date
PL18183987.9T PL3415616T3 (pl) 2011-04-08 2012-04-10 Sposób odmładzania komórek
PL12712670T PL2694642T3 (pl) 2011-04-08 2012-04-10 Sposób odmładzania komórek

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL12712670T PL2694642T3 (pl) 2011-04-08 2012-04-10 Sposób odmładzania komórek

Country Status (7)

Country Link
US (4) US9476031B2 (pl)
EP (3) EP3415616B1 (pl)
JP (3) JP6584776B2 (pl)
CN (1) CN103562376B (pl)
ES (2) ES2991402T3 (pl)
PL (2) PL3415616T3 (pl)
WO (1) WO2012136841A1 (pl)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140051600A1 (en) * 2012-08-16 2014-02-20 Mandala Biosciences Llc SUPERCENTENARIAN INDUCED PLURIPOTENT STEM (sciPS) CELLS AND METHODS OF MAKING AND USING THEREOF
EP2986710A4 (en) * 2013-04-16 2016-11-09 Sloan Kettering Inst Cancer AGE-MODIFIED CELLS AND METHOD FOR PRODUCING AGED-MODIFIED CELLS
US11718832B2 (en) 2014-10-06 2023-08-08 Memorial Sloan-Kettering Cancer Center Method to reduce oncogenic potential of induced pluripotent stem cells from aged donors
WO2016063192A1 (en) * 2014-10-21 2016-04-28 Consiglio Nazionale Delle Ricerche New methods and agents for cellular reprogramming
WO2016185481A2 (en) 2015-05-20 2016-11-24 Yeda Research And Development Co. Ltd. Method of targeting senescent cells
CN105061594B (zh) * 2015-07-16 2019-03-19 中国人民解放军第二军医大学 一种抗人Oct4单克隆抗体及其制备与应用
US20180245051A1 (en) * 2015-11-02 2018-08-30 Orig3N, Inc. Methods for generating induced pluripotent stem cells via cell cycle synchronization
JP2018531610A (ja) * 2015-11-02 2018-11-01 オリジェン， インコーポレイテッド 細胞周期ブロックは、人工多能性幹細胞の生成効率を改善する
WO2018148409A1 (en) * 2017-02-08 2018-08-16 Orig3N, Inc. Systems, methods, and apparatus for induced pluripotent stem cell isolation and combinatorial production
WO2019166702A1 (fr) 2018-02-28 2019-09-06 Hagalife Utilisation d'un procédé d'irradiation flash pour augmenter la longévité et/ou pour retarder les effets du vieillissement chez les mammifères
SG11202008839WA (en) * 2018-03-13 2020-10-29 Univ Leland Stanford Junior Transient cellular reprogramming for reversal of cell aging
CN110628821B (zh) * 2018-06-25 2022-02-18 首都医科大学宣武医院 一种细胞模型及其制备方法、应用
JP7241483B2 (ja) * 2018-07-23 2023-03-17 株式会社ノエビア 皮膚用組成物
WO2020069339A1 (en) 2018-09-28 2020-04-02 President And Fellows Of Harvard College Mutant reverse tetracycline transactivators for expression of genes
WO2020069373A1 (en) * 2018-09-28 2020-04-02 President And Fellows Of Harvard College Cellular reprogramming to reverse aging and promote organ and tissue regeneration
US12274733B2 (en) 2018-09-28 2025-04-15 President And Fellows Of Harvard College Cellular reprogramming to reverse aging and promote organ and tissue regeneration
WO2020206187A1 (en) * 2019-04-02 2020-10-08 Centagen, Inc Engineered system of stem cell rejuvenation to treat aging and disease
GB201909975D0 (en) * 2019-07-11 2019-08-28 Babraham Inst Novel reprogramming method
IL275186A (en) 2020-06-07 2022-01-01 Yeda Res & Dev Human antibodies against grp94 and uses
JP2023544324A (ja) * 2020-10-02 2023-10-23 フェイト セラピューティクス，インコーポレイティド 人工多能性幹細胞のための改善されたリプログラミング、維持及び保存
AU2021386370A1 (en) * 2020-11-24 2023-06-22 Lyell Immunopharma, Inc. Methods for making, compositions comprising, and methods of using rejuvenated t cells
EP4163379A4 (en) * 2020-12-22 2024-08-14 Institute Of Zoology, Chinese Academy Of Sciences METHOD FOR IDENTIFYING AND/OR REGULATING SENESCENCE
US20230044997A1 (en) * 2021-07-15 2023-02-09 Turn Biotechnologies, Inc. Synthetic, persistent rna constructs and methods of use for cell rejuvenation and for treatment
WO2023205406A1 (en) * 2022-04-21 2023-10-26 Restoration Biologics Llc Nutritional or dietary supplement to enhance regenerative medicine therapies
EP4584366A1 (en) 2022-09-06 2025-07-16 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Engineering sox/oct heterodimerization to induce high-grade developmental reset
CN115607689A (zh) * 2022-10-13 2023-01-17 呈诺再生医学科技(北京)有限公司 Klf7基因在制备逆转细胞衰老的药物中的应用
US12252518B2 (en) 2023-01-06 2025-03-18 Life Biosciences, Inc. Methods of treating non-arteritic anterior ischemic optic neuropathy
CN119265241A (zh) * 2023-06-30 2025-01-07 深圳菁童生命科学有限公司 一种无相分离转录因子介导启始阶段重编程使细胞年轻化的方法
KR20260040009A (ko) * 2023-07-11 2026-03-23 난징 레주 테라퓨틱스 컴퍼니 리미티드 조성물 및 이의 사용 방법
WO2025166291A1 (en) * 2024-02-01 2025-08-07 Immorta Bio, Inc. Systemic means of dedifferentiation
WO2026125617A1 (en) * 2024-12-11 2026-06-18 Universidad San Francisco De Quito Usfq Method for conditioning cells and inducing a regenerative phenotype

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2383790C (en) * 1999-09-07 2016-11-22 Advanced Cell Technology, Inc. Telomere restoration and extension of cell life-span in animals cloned from senescent somatic cells
EP2206724A1 (en) 2005-12-13 2010-07-14 Kyoto University Nuclear reprogramming factor
AU2008297024B2 (en) 2007-10-31 2014-08-28 Kyoto University Nuclear reprogramming method
EP2268796A1 (en) 2008-03-17 2011-01-05 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Vectors and methods for generating vector-free induced pluripotent stem (ips) cells using site-specific recombination
WO2010008054A1 (ja) * 2008-07-16 2010-01-21 ディナベック株式会社 染色体非組み込み型ウイルスベクターを用いてリプログラムされた細胞を製造する方法
WO2010042490A1 (en) 2008-10-06 2010-04-15 Boston Medical Center Corporation A single lentiviral vector system for induced pluripotent (ips) stem cells derivation
WO2010105311A1 (en) * 2009-03-20 2010-09-23 Angioblast Systems, Inc. Production of reprogrammed pluripotent cells
US8900871B2 (en) * 2009-08-07 2014-12-02 Kyoto University Method of producing induced pluripotent stem cells using inhibitors of P53

Also Published As

Publication number Publication date
JP6584776B2 (ja) 2019-10-02
ES2991402T3 (es) 2024-12-03
US20160376560A1 (en) 2016-12-29
JP2017140040A (ja) 2017-08-17
JP2019151660A (ja) 2019-09-12
EP2694642A1 (en) 2014-02-12
EP3415616A1 (en) 2018-12-19
JP2014511689A (ja) 2014-05-19
EP2694642B8 (en) 2018-10-17
EP4382171A2 (en) 2024-06-12
PL2694642T3 (pl) 2019-01-31
ES2695550T3 (es) 2019-01-09
US20180312813A1 (en) 2018-11-01
US9476031B2 (en) 2016-10-25
US11414649B2 (en) 2022-08-16
US20140056860A1 (en) 2014-02-27
CN103562376A (zh) 2014-02-05
EP3415616B1 (en) 2024-05-22
WO2012136841A1 (en) 2012-10-11
US20200095556A1 (en) 2020-03-26
CN103562376B (zh) 2017-12-29
EP2694642B1 (en) 2018-08-15
JP7051748B2 (ja) 2022-04-11
EP4382171A3 (en) 2024-10-09

Similar Documents

Publication Publication Date Title
DK2776833T3 (da) Cobinder-understøttet testfremgangsmåde
BR112014009795A2 (pt) método
BR112014007958A2 (pt) método
BR112012015988A2 (pt) método
DK2732131T3 (da) Positioneringsfremgangsmåde
BR112014001851A2 (pt) método
BR112014001237A2 (pt) método
DK2744810T4 (da) Tenofovir-alafenamid-hemifumarat
EP2715659A4 (en) ABOUT FEED
DK3272861T3 (da) Alpha-galactosidase-sammensætninger
EP2701512A4 (en) Aldosterone synthase inhibitors
CO6960543A2 (es) 2-tiopirimidinonas
BR112013009024A2 (pt) método
DK3141251T3 (da) Koloskopi - forberedelse
BR112012023891A2 (pt) método
EP2824694A4 (en) STRUCTURE FORMATION METHOD
DE112011104936A5 (de) Stanzstauchniet
IL227295A0 (en) Diagnostic method
EP2771685A4 (en) BIOMARKERS OF CANCER
FI20125179L (fi) Menetelmä kelluttamiseksi
HUE056468T2 (hu) Eljárás mikrokapszulák nyerésére
EP2729467A4 (en) CRYPTATE COMPOUNDS
BR112012033000A2 (pt) método
DE112012003417A5 (de) Strommessgerät
EP2771952C0 (en) SIGN